← All devices 
Clinical / medical-grade · Patch / sensor · by Dexcom
Dexcom G7 / Stelo
Insulin-dosing-grade continuous glucose, with CSV export, clinician sharing, and an OTC option.
February 2023Dexcom G7 (Stelo, Aug 2024)
Maturing3 yr 4 mo old
CGM platform — iterates continuously (G7 15-Day cleared 2025).
API access: Yes — open Raw data access: Yes — open Open source: Community
Clinical value
92/100
Dosing-grade, AID-integrated CGM
Empowerment
70/100
Good export & sharing, Rx gate
Everyday value
56/100
Forgettable sensor, single-purpose
A continuous glucose monitor accurate enough to dose insulin and drive automated insulin-delivery systems, with solid patient data export — tempered by prescription gatekeeping on the medical-grade version.
What it measures
Continuous interstitial glucose every 5 min (G7) or 15 min (Stelo), real-time alerts/alarms (G7), and insulin-pump / automated-insulin-delivery integration.
Regulatory status
G7: 510(k)-cleared integrated CGM (iCGM), ages 2+; a 15-Day version cleared in 2025. Stelo: first FDA-cleared OTC glucose biosensor (2024), adults not on insulin, no urgent-low alarm.
Validation & accuracy
G7 ~8.2% MARD; G7 15-Day ~8.0% MARD in pivotal testing. Stelo ~10% MARD. Among the most accurate CGMs.
Data control & export
Dexcom Clarity generates PDF reports and CSV export; Dexcom Follow gives real-time caregiver sharing; clinic data-sharing via Clarity invitation.
Wearability & battery
Small adhesive sensor on the upper arm, 10-day wear (G7) or 15-day (G7 15-Day). No charging — you replace each sensor. Lightweight and largely forgettable; adhesive can irritate some skin.
Cost & access
G7 by prescription, broadly covered by commercial insurance and Medicare. Stelo OTC ~$89/sensor (~$99/2-pack subscription), not insurance-covered.
Who it serves
Strong on clinician sharing, caregiver Follow, and raw CSV export; the G7 path still runs through a prescription and a proprietary app.
Who is left out or burdened
Rx gatekeeping for G7; Stelo excludes insulin users and omits hypo alarms; ongoing sensor cost.
✓ Strengths
- Dosing-grade accuracy (~8% MARD); AID integration
- Raw CSV + PDF reports; developer API
- Real-time caregiver and clinic sharing
- OTC Stelo option; broad insurance coverage
✕ Weaknesses
- G7 requires a prescription
- 2025 FDA warning letter over manufacturing
- Proprietary app; ongoing sensor cost
- Stelo excludes insulin users, no hypo alarm
92
Why this clinical score. Dosing-grade accuracy, AID integration, and broad clinical use put it at the top of the clinical axis.
70
Why this empowerment score. CSV + PDF + caregiver and clinician sharing are genuinely empowering, but prescription gatekeeping and the proprietary app ecosystem cap the score.
56
Why this everyday score. Comfortable, no charging, and easy to live with — but it does one thing and means recurring sensor changes and cost, so everyday breadth is limited.
Latest news
Reviews & coverage
Reviewers and clinicians rate Dexcom G7 among the most accurate CGMs, praising fast warm-up, reliable alerts and broad app/integration support. The caveats are cost and the occasional compression-low or sensor dropout.
Summary is a draft synthesis of public coverage, not an endorsement. Links open a search of each outlet.
Reddit communities
Independent user communities where this device (or its category) is discussed.
Get it · manuals & support
Draft profile · public-source review, June 2026 · scores describe direction and degree, not buying advice. News, links, and prices change — verify with the manufacturer. Image is representative.